Reliance Life Sciences offers the following
molecular medicine services:
- DNA/RNA Diagnostics
- Molecular Genetics
- Predictive Diagnostics
The Molecular Diagnostics and Genetics laboratories are accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL) and the College of American Pathologists (CAP).
DNA/RNA Diagnostics
Reliance
Life Sciences provides DNA/RNA based diagnostics
services for infectious diseases, qualitative
tests for detection and quantitative assessment
of the viral/bacterial load of infectious
agents, including viruses - HIV, HCV, HBV,
CMV, Parvo, Japanese Encephalitis Virus,
BK virus, Bacteria like TB, Typhoid, and
Protozoa - Plasmodium species and associated
organisms like HCV, HBV, TB and CMV, using
PCR, PCR-Sequencing (for genotyping) and
Real Time PCR for precise quantification
of viral and bacterial load, as also for
expression analysis.
Specialised PCR testing is also provided
for HLA typing, exon deletions for Duchenne
Muscular Dystropy, mitochondrial mutations
for associated neurological diseases, Beta
Thalassemia mutations for globin gene and
Y chromosome deletion for male infertility
investigations, among others.
Reliance Life Sciences is focussing on the
contemporary field of Theranostics, with
equivalent emphasis on diagnostics and therapy.
Thus, selection of patients for optimal
treatment with targeted therapy such as
monoclonal antibodies or small molecules
to EGF-R, requires molecular diagnostics
to detect K-ras mutations in metastatic
colon cancers, EGF-R mutations in Non-small
cell lung cancers; or MGMT methylation to
select patients for treatment with Temozolomide.
These and several tests grouped in the field
of Theranostics are offered at Reliance
Life sciences.
Reliance Life Sciences has ongoing research
programs on genotype-phenotype correlations
in several cancers of significance in the
Indian context, including Oral Cancer, Breast
Cancer, Cervical Cancer and Colon Cancer,
with the ultimate goal of developing predictive
markers in human cancers and understanding
their molecular pathology. The group aims
to define single nucleotide polymorphisms
indicative of high risk related to cardiovascular
disease and vitiligo and establish predictive
diagnostics for cancers (breast, cervical,
colon and oral).
To know more about the molecular diagnostics
testing services available,
click
here.
Molecular Genetics
Reliance
Life Sciences is involved in cytogenetic
research and provides cytogenetic testing
services using modified Karyotyping and
Fluorescence In-Situ Hybridization (FISH)
based assays to detect numerical and structural
chromosomal abnormalities, including translocations,
amplifications and micro-deletions in peripheral
blood cells, bone marrow, products of conception,
chorionic villi, amniotic fluid and cord
blood.
Prenatal diagnosis for all karyotypic aberrations
and rapid FISH based assays for Down's syndrome,
Chronic Myeloid Leukemia and Acute Promyelocytic
Leukemia, add to the repertoire of essential
high-end molecular genetic testing services
offered by Reliance Life Sciences.
To know more about the genetics testing
services available,
click
here
Predictive Diagnostics
Reliance Life Sciences is involved in Predictive
Diagnostics research in the field of Oncology,
with the objective of predicting increased
risk of developing a disease in the future
based on a test done on an asymptomatic
person (person who appears normal). Positive
result only provides information about a
person's risk of developing Cancer. Negative
result indicates the individual's risk of
cancer is the same as that of general population.
Reliance Life Sciences was the first organization
doing BRCA 1/ BRCA 2 mutations testing for
familial breast cancer in India. Reliance
Life Sciences uses state-of-the-art technology
i.e. DNA sequencing - 'a gold standard'
and the test shows 100 percent sensitivity
and specificity. Reliance Life Sciences
offers both pre and post genetic counselling
and reports both the alterations depicting
the polymorphisms observed and the mutations.
Turn around time (TAT) for BRCA1/BRCA2 is
a record fifteen days, which is the best
TAT for BRCA1/BRCA2 globally. BRCA 1/BRCA2
TAT at most labs in the world is approximately
three to six months.
Reliance
Life Sciences also offers predictive tests
for RET gene mutations for familial Medullary
Thyroid Cancer, Microsatellite Instability
for Colon Cancer and Human Papilloma Virus
(HPV) detection and typing by nucleotide
sequencing, for depicting increased risk
of Cervical Cancer.
Tests are also available for predicting
the probability of an individual for stroke,
heart attack etc.. These tests study three
Cardio-Vascular diseases (CVD) risk markers
- Factor V Leiden, MTHFR and Prothombin
gene mutation, which accounts to around
45% of the total thrombotic risk factors.
To know more about predictive diagnostics
testing services available,
click
here
